BioNTech to Lay Off 1,860 Employees Due to Overcapacity

German biotechnology company BioNTech has announced it will lay off 1,860 employees as part of cost-cutting measures. The company has decided to close some production facilities and refocus its strategy on cancer drugs. The layoffs are seen as part of an effort to manage overcapacity resulting from declining demand for its COVID-19 vaccine. BioNTech aims to improve operational efficiency and achieve long-term growth targets through this move. Unions have strongly criticized the layoff decision, expressing concerns about the future of employees. BioNTech's move reflects changing dynamics in the global biotechnology sector. This is not investment advice.

📊 BNT — Piyasa Yorumu

▼ down · 60%

The news indicates that BioNTech will lay off employees due to excess capacity. This situation could negatively affect the company's growth expectations and create selling pressure on the crypto asset BNT. Although technical indicators show a neutral trend, the RSI at 54 and the MACD remaining below the signal line point to weak momentum. A short-term bearish bias may prevail, but the impact could be limited.

RSI 14

54.7

MACD

0.00

24h Δ

0.48%

Canlı Grafikler